Immutep reports strong cancer trial results
Immutep (ASX:IMM) has made significant progress over the past year with its lead immunotherapy candidate, eftilagimod alpha (efti).
Read MoreTag: IMM
Immutep (ASX:IMM) announces positive results in head and neck cancer treatment
Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the company's latest results in head and neck cancer.
Read MoreStocks of the Hour: Immutep, Lepidico, Mithril Silver and Gold
A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Lepidico (ASX:LPD) and Mithril Silver and Gold (ASX:MTH).
Read MoreImmutep (ASX:IMM) reports first subject dosed in autoimmune disease study
Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress with the company's IMP761 drug, which is potentially active in more than 90% of autoimmune diseases.
Read MoreStocks of the Hour: Immutep, LiveHire, Forbidden Foods, Estrella Resources
A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), LiveHire (ASX:LVH), Forbidden Foods (ASX:FFF) and Estrella Resources (ASX:ESR).
Read MoreClinical trials in cancer and autoimmune diseases: Immutep’s CEO Marc Voigt provides an update
Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses Phase III design for a trial in non-small cell lung cancer, positive results in head and neck cancer, and clearance for a Phase I study in autoimmune diseases.
Read MoreImmutep receives positive FDA feedback
Immutep (ASX:IMM; NASDAQ:IMMP), a leading biotechnology firm specialising in LAG-3 immunotherapy, has achieved a significant milestone in its quest to redefine cancer treatment.
Read MoreStocks of the Hour: Immutep, Middle Island Resources, Inca Minerals
A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Middle Island Resources (ASX:MDI) and Inca Minerals (ASX:ICG).
Read MoreImmutep (ASX:BLA) – TACTI-003 positive data in patients with negative PD-L1 expression (cohort B)
Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Medical Officer Dr Florian Vogl, and Senior Vice President Strategic Development Christian Mueller present on Immutep's latest clinical results.
Read MoreImmutep (ASX:IMM) TACTI-003 results, June 2024
Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific Officer Professor Frédéric Triebel, Chief Medical Officer Dr Florian Vogl, and Senior Vice President Strategic Development Christian Mueller present on Immutep's latest clinical results.
Read MoreStocks of the Hour: Immutep, INOVIQ, Eastern Metals
A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), INOVIQ (ASX:IIQ) and Eastern Metals (ASX:EMS).
Read MoreStocks of the Hour: Krakatoa Resources, Immutep, ABx Group
A snapshot of the stocks on the move, featuring Krakatoa Resources (ASX:KTA), Immutep (ASX:IMM) and ABx Group (ASX:ABX).
Read MoreStocks of the Hour: Immutep, Western Mines Group, Industrial Minerals
A snapshot of the stocks on the move, featuring Immutep (ASX:IMM; NASDAQ:IMMP), Western Mines Group (ASX:WMG) and Industrial Minerals (ASX:IND).
Read MoreStocks of the Hour: Nimy Resources, New Age Exploration, Immutep
A snapshot of the stocks on the move, featuring Nimy Resources, New Age Exploration and Immutep.
Read MoreEncouraging results for Immutep’s cancer therapies
Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt provides an update on the company's pipeline of clinical trials, focusing on results in head and neck cancer, lung cancer and breast cancer.
Read MoreImmutep (ASX:IMM) – Webinar Presentation
Marc Voigt, Executive Director & CEO, Immutep (ASX:IMM) is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 immunotherapy for cancer and autoimmune diseases.
Read MoreStocks of the Hour: Immutep, Metalicity, GWR Group
A snapshot of the stocks on the move, featuring Immutep (ASX:IMM; NASDAQ:IMMP), Metalicity (ASX:MCT) and GWR Group (ASX:GWR).
Read MoreStocks of the Hour: Sunstone Metals, Immutep, European Metals Holdings, QX Resources
A snapshot of the stocks on the move, featuring Sunstone Metals (ASX:STM), Immutep (ASX:IMM, NASDAQ:IMMP), European Metals Holdings (ASX:EMH & AIM:EMH) and QX Resources (ASX:QXR).
Read MoreStocks of the Hour: Whispir, QX Resources, Immutep, Magnis Energy Tech
A snapshot of the stocks on the move, featuring Whispir (ASX:WSP), QX Resources (ASX:QXR), Immutep (ASX:IMM) and Magnis Energy Technologies (ASX:MNS).
Read MoreStocks of the Hour: Findi, Immutep, ImpediMed
A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), ImpediMed (ASX:IPD) and Findi (ASX:FND).
Read MoreImmutep (ASX:IMM) reports 71.4% response rate for lung cancer therapy
Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress of the company's drug candidates, highlighting promising data from the 2023 ESMO Congress.
Read MoreStocks of the Hour: Immutep, Empire Energy, Lincoln Minerals
A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Empire Energy (ASX:EEG) and Lincoln Minerals (ASX:LML).
Read MoreStocks of the Hour: Immutep, Vulcan Energy Resources, Australian Gold and Copper
A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Vulcan Energy Resources (ASX:VUL) and Australian Gold and Copper (ASX:AGC).
Read MoreImmutep makes headway in late-stage trials
Immunotherapy company Immutep has released its Quarterly Activities report, which highlights significant progress in late-stage and registrational trials.
Read MoreASX down 0.8% at noon as Australian retail sales fall
Australian retail sales experienced a 0.8% decline last month, as reported by the Australian Bureau of Statistics. This result came as a surprise to markets, which had anticipated a steady performance for June following a robust 0.7% gain in May.
Read MoreStocks of the Hour: Immutep, Pointerra, Zeus Resources
A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Pointerra (ASX:3DP) and Zeus Resources (ASX:ZEU).
Read MoreImmutep (ASX:IMM) – Webinar Presentation
Marc Voigt – Executive Director & CEO – Immutep (ASX:IMM) is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 immunotherapy for cancer and autoimmune diseases.
Read MoreImmutep’s Positive FDA Talks and Strong Survival Data
Immutep Executive Director and CEO Marc Voigt discusses the significance of recent announcements on the back of a recent surge in trading volume.
Read MoreImmutep (ASX: IMM) Delivering Strong Lung Cancer Data
Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses data from the SITC Conference in Boston, the strategy to take Efti to market and milestones for 2023.
Read MoreImmutep (ASX: IMM) – Webinar Presentation
Marc Voigt – Executive Director & CEO – Immutep is a leading biotechnology company focused on developing effective autoimmune and cancer immunotherapy treatments such as Lag-3.
Read MoreImmutep (ASX: IMM) – A Transformative Year for LAG-3 Therapies
Immutep CEO Marc Voigt discusses the LAG-3 landscape, the company’s portfolio of therapies, encouraging data from the 2022 SITC conference and the outlook for 2023.
Read MoreImmutep (ASX: IMM) Receives Fast Track Designation from FDA
Immutep CEO Marc Voigt discusses the FDA fast track designation received in first-line non-small cell lung cancer, the company’s new Phase 2 trial in soft tissue sarcoma and the outlook ahead.
Read MoreImmutep (ASX:IMM) granted Japanese patent for IMP761
Immutep (ASX:IMM) has granted a Japanese patent for its IMP761, an immunosuppressive agonist antibody targeting LAG-3 for autoimmune diseases.
Read MoreImmutep (ASX:IMM) TACTI-002 data presented at ASCO 2022
Immutep Limited ED / CEO Marc Voigt, Chief Scientific and Medical Officer Dr Frédéric Triebel, and Vice President Strategic Development Christian Mueller present on Immutep’s latest clinical results.
Read MoreImmutep Limited (ASX:IMM) Investor Presentation
Immutep Limited CEO Marc Voigt provides an overview of the company, discussing the LAG-3 immune checkpoint and pipeline, eftilagimod alpha’s potential, and ongoing clinical trials.
Read MoreHow Immutep Treats Head & Neck Cancer
ShareCafe spoke with Marc Voigt, CEO of local biotech Immutep, about the progress his company is making specifically in the area of head and neck cancer treatments.
Read MoreLatest from Immutep (ASX: IMM) on LAG-3 and 2022 Outlook
The attached video covers biotech company Immutep’s latest news on their Lymphocyte Activation Gene-3 (LAG-3) treatment and outlook for the coming 12 months.
Read MoreImmutep Taking the Fight to Cancer
Following on from his previous report on the company, Corporate Connect analyst Marc Sinatra has today published an updated analysis of ASX-listed biotech Immutep Ltd (ASX: IMM), valuing IMM at $A2.20 per share.
Read MoreImmutep Leading the development of immunotherapy for cancer and autoimmune diseases
Pengana Fund manager James McDonald provides insight into why he believes biotech Immutep is very well placed to benefit from the current environment and how it fits in the portfolio structure.
Read MoreInstitutions Support Immutep Capital Raising
Australian biotech company Immutep has announced it has completed the second tranche of its institutional placement at an issue price of A$0.52 per share to raise approximately A$46.3 million.
Read More
